Re Licence Agreement

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

                        Licence Agreement in HTS Stroke                        

June 28, 2006. Proteome Sciences plc ("Proteome Sciences") is pleased to
announce a licence agreement with one of the top 10 global leaders in clinical
diagnostics to use its biomarkers for the detection, diagnosis and monitoring
of stroke. This is a new area for the licencee who has determined not to
disclose its identity at this time for competitive reasons. The biomarkers were
discovered and validated using a combination of different proteomic approaches
available for external use through the proprietary ProteoSHOP® platform.

Stroke is the brain equivalent of a heart attack. Blood must flow in and
through the brain for it to function. If its flow is obstructed by a blood clot
moving to the brain or by narrowing or blocking of blood vessels, the brain
loses its energy supply, causing damage to tissues leading to stroke.

Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million
die and another 5 million are left permanently disabled, placing a burden on
family and community.

Stroke is the third leading cause of death in the US (160,000 deaths) with
annual costs of $57.9bn for stroke-medical related costs and disability and the
single most common cause of severe disability. 750,000 people are diagnosed in
the US annually having new or recent strokes.

Under the research licence, a number of Proteome Sciences biomarkers will be
tested in stroke for inclusion on a new panel for the licencee's
high-throughput diagnostic platforms. No financial details were disclosed.

The preliminary announcement of Proteome Sciences results for the year ended
31st December, 2005 will be released by 30th June, 2006.

Christopher Pearce, CEO of Proteome Sciences, said:

" This licencee is world renowned in clinical diagnostics and has built a
strong customer base ideally placed to introduce and support new stroke
diagnostic products globally. This reflects their commitment to develop
innovative assays and solutions to address the major unmet diagnostic and
prognostic needs in stroke.

They have been impressed by Proteome Sciences' ProteoSHOP® technology to
discover novel biomarkers in blood and to progress these rapidly for the market
place. This agreement brings important new biomarkers to their IVD pipeline and
the opportunity to diagnose stroke in a high- throughput system. We look
forward to incorporation of our stroke markers onto their systems and to a
rapid introduction of an HTS stroke test."

                                   - Ends -                                    

Notes to Editors:

Stroke

Stroke is the brain equivalent of a heart attack. Blood must flow in and
through the brain for it to function. If its flow is obstructed by a blood clot
moving to the brain or by narrowing or blocking of blood vessels, the brain
loses its energy supply, causing damage to tissues leading to stroke.

Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million
die and another 5 million are left permanently disabled, placing a burden on
family and community.

Stroke is the third leading cause of death in the US (160,000 deaths) with
annual costs of $57.9bn for stroke-medical related costs and disability and is
the single most common cause of severe disability. 750,000 people are diagnosed
in the US annually having new or recent strokes.

Proteome Sciences plc

Proteome Sciences plc, a global leader in applied proteomics, uses high
sensitivity proprietary technologies to detect differentially expressed
proteins in diseases. The protein biomarkers discovered in body fluids or
tissues are validated, developed and commercialised as diagnostic, prognostic
or therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™ & TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers. Chemical
mass tags for isobaric labelling have been developed as stand-alone reagents.

For further information please visit www.proteomics.com

Enquiries:

Proteome Sciences plc

Christopher Pearce Chief Executive

James Malthouse Finance Director

Tel: [phone]

Fax: [phone]

Email: [e-mail]

Public Relations for Proteome Sciences

IKON Associates

Adrian Shaw

Tel: [phone]

Mobile: [phone]

Email: [e-mail]